Efficacy of letrozole in treatment of children with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency

doi:10.3785/j.issn.1008-9292.2020.04.04

J Zhejiang Univ (Med Sci)

2020, Vol. 49

Issue (3): 302-307 DOI: 10.3785/j.issn.1008-9292.2020.04.04

Efficacy of letrozole in treatment of children with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency

WANG Qian¹(

),ZHANG Shule²,MA Xue²,LI Guimei^1,*(

),WANG Zengmin¹,WANG Fengxue¹

1. Department of Pediatric Endocrine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250014, China
2. Department of Pediatric Endocrine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250014, China

Download:

HTML( 7 )

PDF(1030KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To assess the efficacy of letrozole in treatment of children with congenital adrenal hyperplasia (CAH) due to steroid 21-hydroxylase deficiency (21-OHD). Methods: Twenty eight children, including 19 boys and 9 girls aged 4-10y, with CAH due to 21-OHD were enrolled in the study. At the first six months of study, all children received conventional treatment with hydrocortisone or fludrocortisone, then letrozole was added to original regimen. The height velocity (HV), difference between bone age and chronological age (BA-CA), height standard diviation score based on bone age (HtSDS_BA), predicted adult height (PAH), Tanner phase, sex hormone, and possible adverse reaction were evaluated and compared between those before and after letrozole treatment. Results: After 6 months of letrozole treatment, there was significant deceleration of HV, but it would recover soon. There was significant increase of HtSDS_BA after 12 months of letrozole treatment (P < 0.05 or P < 0.01), and significant changes in BA-CA after 18 months of letrozole treatment (P < 0.05). PAH of female children was significantly increased during letrozole treatment (P < 0.05), whereas PAH of male children was significantly increased 18 months after letrozole treatment (P < 0.05). Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were significantly increased, but did not meet the diagnostic criteria of central precocious puberty. Estradiol was significantly decreased (P < 0.01), but no changes in testosterone level was observed. During 24 months letrozole treatment, no hirsutism, severe acne, headache, bone pain, obesity, hypertension, rash and other adverse reactions were observed. Conclusions: Letrozole can delay bone maturation and improve PAH, which can be used with conventional treatment for children with CAH due to 21-OHD, especially for those with high BA and low PAH.

Key words： Adrenal hyperplasia, congenital 21-hydroxylase deficiency Child Aromatase inhibitors Letrozole Treatment outcome Safety Adrenal hyperplasia, congenital 21-hydroxylase deficiency Child Aromatase inhibitors Letrozole Treatment outcome Safety

Received: 04 December 2019 Published: 29 May 2020

CLC:	R588
	R725.8
	R588
	R725.8

Corresponding Authors: LI Guimei E-mail: wangqian8482752@163.com;liguimei2013@126.com

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qian
	ZHANG Shule
	MA Xue
	LI Guimei
	WANG Zengmin
	WANG Fengxue

Cite this article:

WANG Qian,ZHANG Shule,MA Xue,LI Guimei,WANG Zengmin,WANG Fengxue. Efficacy of letrozole in treatment of children with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Zhejiang Univ (Med Sci), 2020, 49(3): 302-307.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.04.04 OR http://www.zjujournals.com/med/Y2020/V49/I3/302

来曲唑对21-羟化酶缺乏型先天性肾上腺皮质增生症患儿生长发育的影响

目的: 探讨来曲唑联合常规方法治疗21-羟化酶缺乏型先天性肾上腺皮质增生症（CAH）患儿的可行性。方法: 选取2010年12月至2016年1月确诊的4~10岁21-羟化酶缺乏型CAH患儿共28例，其中男性19例，女性9例。入组患儿前6个月为常规治疗（氢化可的松、氟氢可的松），第6个月末开始加用来曲唑联合治疗。通过自身前后对照的方法，对联合治疗前后患儿的骨龄进展速度、预期成年身高、性征发育程度及性激素水平、可能的不良反应等指标进行统计。结果: 加用来曲唑联合治疗后，患儿身高增长速度在短期（6个月内）有所下降，但很快恢复正常；联合治疗12个月后患儿骨龄别身高标准差分值（HtSDS_BA）较入组时及常规治疗均显著改善（P < 0.05或P < 0.01）；骨龄与时序年龄差值在联合治疗18个月后较常规治疗显著改善（P < 0.05）；女性患儿预期成年身高在联合治疗12个月后较常规治疗显著改善（P < 0.05），男性患儿在联合治疗18个月后预期成年身高亦显著改善（P < 0.05）；患儿卵泡刺激素、促黄体生成素升高，但未达到中枢性性早熟标准；患儿雌二醇水平降低（P < 0.01）；患儿睾酮水平无显著改变。来曲唑联合治疗24个月，患儿未见多毛、严重痤疮、头疼、骨痛、肥胖、高血压、皮疹等不良反应。结论: 来曲唑联合常规治疗的方案可用于21-羟化酶缺乏型CAH患儿长期治疗，特别是骨龄明显超期、预期成年身高受损的患儿，可实现抑制骨龄进展、改善预期成年身高的治疗目的。

关键词： 肾上腺增生, 先天性, 21-羟化酶缺乏症, 儿童, 芳香酶抑制剂, 来曲唑, 治疗效果, 安全性, 肾上腺增生, 先天性, 21-羟化酶缺乏症, 儿童, 芳香酶抑制剂, 来曲唑, 治疗效果, 安全性

Tab 1 Differences of height velocity, bone age and predicted adult height in different time points (${\bar x}$±s)

Tab 2 Changes in sex hormones after letrozole treatment (${\bar x}$±s)


[1]	EL-MAOUCHE D , ARLT W , MERKE D P . Congenital adrenal hyperplasia[J]. Lancet, 2017, 390 (10108): 2194- 2210 doi: 10.1016/S0140-6736(17)31431-9

[2]	MERKE D P , KEIL M F , JONES J V et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia[J]. J Clin Endocrinol Metab, 2000, 85 (3): 1114- 1120 doi: 10.1210/jcem.85.3.6462

[3]	PIGNATELLI D , PEREIRA S S , PASQUALI R . Androgens in congenital adrenal hyperplasia[J]. Front Horm Res, 2019, 53 65- 76 doi: 10.1159/000494903

[4]	MUTHUSAMY K , ELAMIN M B , SMUSHKIN G et al. Clinical review:Adult height in patients with congenital adrenal hyperplasia:a systematic review and metaanalysis[J]. J Clin Endocrinol Metab, 2010, 95 (9): 4161- 4172 doi: 10.1210/jc.2009-2616

[5]	JUAN L , HUAMEI M , ZHE S et al. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency:a single-center study from China[J]. J Pediatr Endocrinol Metab, 2016, 29 (7): 841- 848 doi: 10.1515/jpem-2015-0406

[6]	MAHESHWARI A , KHADILKAR V , GANGODKAR P et al. Long-term growth in congenital adrenal hyperplasia[J]. Indian J Pediatr, 2019, 86 (2): 154- 158 doi: 10.1007/s12098-018-2753-6

[7]	GVVEN A , NURCAN CEBECI A , HANCILI S . Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty[J]. Hormones (Athens), 2015, 14 (2): 265- 271 doi: 10.14310/horm.2002.1555

[8]	中华医学会儿科学分会内分泌遗传代谢病学组 . 先天性肾上腺皮质增生症21-羟化酶缺陷诊治共识[J]. 中华儿科杂志, 2016, 56 (8): 569- 575 Group of Pediatric Endocrine and Genetic Metabolic, Chinese Pediatric Society, Chinese Medical Association . Diagnosis and treatment of congenital adrenal hyperplasia with 21-hydroxylase deficiency[J]. Chinese Journal of Pediatrics, 2016, 56 (8): 569- 575 doi: 10.3760/cma.j.issn.0578-1310.2016.08.003

[9]	李辉, 季成叶, 宗心南 et al. 中国0~18岁儿童、青少年身高、体重的标准化生长曲线[J]. 中华儿科杂志, 2009, 47 (7): 487- 490 LI Hui , JI Chengye , ZONG Xinnan et al. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years[J]. Chinese Journal of Pediatrics, 2009, 47 (7): 487- 490 doi: 10.3760/cma.j.issn.0578-1310.2009.07.003

[10]	THODBERG H H, JUUL A, LOMHOLT J, et al. Adult height prediction models[M]//RODRIGUES D, WOLFORD L. Handbook of Growth and Growth Monitoring in Health and Disease. Springer Science + Business Media, 2012: 27-57.

[11]	潘嘉严, 张先来, 徐东 . TW3成年身高预测改良法在中国儿童中的应用研究[J]. 现代医学, 2018, 46 (7): 773- 780 PAN Jiayan , ZHANG Xianlai , XU Dong . Application of improved TW3 method in predicting adult height in Chinese children[J]. Modern Medical Journal, 2018, 46 (7): 773- 780 doi: 10.3969/j.issn.1671-7562.2018.07.011

[12]	SHULMAN D I, FRANCIS G L, PALMERT M R, et al. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development[J/OL]. Pediatrics, 2008, 121(4): e975-e983. DOI: 10.1542/peds.2007-2081.

[13]	MAURAS N , ROSS J L , GAGLIARDI P et al. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature[J]. J Clin Endocrinol Metab, 2016, 101 (12): 4984- 4993 doi: 10.1210/jc.2016-2891

[14]	ESTRADA A , BOYCE A M , BRILLANTE B A et al. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome[J]. Eur J Endocrinol, 2016, 175 (5): 477- 483 doi: 10.1530/EJE-16-0526

[15]	LANE L C , FLOWERS J , JOHNSTONE H et al. Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management[J]. J Pediatr Endocrinol Metab, 2018, 31 (5): 551- 560 doi: 10.1515/jpem-2017-0363

[16]	HERO M , NORJAVAARA E , DUNKEL L . Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature:a randomized controlled trial[J]. J Clin Endocrinol Metab, 2005, 90 (12): 6396- 6402 doi: 10.1210/jc.2005-1392

[1]	LI Yanhong,DU Minlian,MA Huamei,CHEN Qiuli,CHEN Hongshan,ZHANG Jun. Efficacy of letrozole in treatment of male adolescents with idiopathic short stature[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 308-314.

[2]	KONG Yuanmei,CHEN Hong,LIANG Li,ZHENG Maoni,FANG Yanlan,WANG Chunlin. Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 283-290.

[3]	WANG Chunlin,LIANG Li. Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 275-282.

[4]	YU Bingqing,NIE Min,WU Xueyan,MAO Jiangfeng,WANG Xi,MA Wanlu,JI Wen,HUANG Qibin,ZHANG Rui. Efficacy and safety of letrozole in treatment of male children with disorders of sex development[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 297-301.

[5]	XU De,LU Wenli,WANG Xueqing,WANG Junqi,XIE Yiwen,DONG Zhiya,WANG Wei. Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 291-296.

[6]	SUN Jinhong,QIU Chenyang,WU Ziheng,ZHANG Hongkun. Preliminary result of stents implantation for spontaneous isolated dissection of the superior mesenteric artery: a prospective single-arm study[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 383-388.

[7]	CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.

[8]	JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.

[9]	CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.

[10]	ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.

[11]	GAO Mingxuan,NIE Dejun,CHANG Yanfeng,XIE Weiqiang,WANG Yue,PU Xingyu,ZHANG Wei,LUO Wenyuan. Internal fixation of lateral and medial borders for displaced scapular body fractures via minimally invasive approach: results of 23 cases[J]. J Zhejiang Univ (Med Sci), 2019, 48(6): 651-656.

[12]	LIN Jing,CHEN Zhimin. Research progress on early identification of severe adenovirus pneumonia in children[J]. J Zhejiang Univ (Med Sci), 2019, 48(5): 567-572.

[13]	ZHANG Lifeng,YANG Hui,ZHANG Xinmei,CHEN Zhengyun. Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 130-135.

[14]	LOU Junyao,HUANG Xiufeng,ZHANG Lifeng,XU Ping,ZHANG Xinmei,CHEN Zhengyun. The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 136-141.

[15]	NIU Yubai,ZHANG Lingyan,HAO Zesheng,JI Yuzhu. Relationship between temperament, parenting style and resilience of children aged 3-5 years[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 75-82.

Viewed

Full text

Abstract

Cited

Shared

Discussed